Cancer Biopsies Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Cancer Biopsies Market is segmented by Product (Instrument, Kits and Consumables, and Services), Type (Tissue Biopsy, Cancer Surgical Biopsy, Liquid Biopsy, and Others), Application (Breast Cancer, Colorectal Cancer, Cervical Cancers, Lung Cancers, and Other Applications), End Users (Hospitals, Diagnostics Laboratories and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

alt
Study Period: 2018-2026
Base Year: 2020
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 6.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Cancer Biopsies Market is expected to grow with an estimated CAGR of 6.5%, over the forecast period.

COVID 19 has a great impact on the medical industry, especially on the cancer biopsies market. In this pandemic due to social distancing measures imposed by the governments, the use of healthcare services and visits to the hospital have drastically reduced, due to which the patients were only allowed /permitted in the case of an emergency. In addition to this according to the Nature Cancer journal, in 2020, the Centers for Medicare and Medicaid Services in the United States have classified screening as a low-priority service during this pandemic. Following this, other countries such as Scotland, Ireland had also suspended the cancer screening programs during COVID 19.

The rise in cancer diseases is also playing a key role in the cancer biopsies market's growth. In 2018, according to International Agency for Research on Cancer (IARC), new cancer cases are expected to grow to 27.5 million and 16.3 million cancer deaths, globally, by 2040. In 2021, according to the National Cancer Institute (NCI) the estimated number of new bladder cancer cases were 83,730 whereas breast cancer cases were 284,200, colon and rectal cancer accounting to149,500 in United States. This indicates a potential elevation of cancer biopsies market in coming years.

The technological advancements and product launches by some of the key players of the market are also attributed to the markets growth. For instance, in Feb 2020, to improve the precision medicine in breast cancer, Qiagen has launched Liquid Biopsy PIK3CA kit. Protein p110α which is made by PIK3CA gene, involved in growth and division of cell, mutation in this gene causes uncontrollable cell growth and division, that leads to cancer. This particular biopsy PIK3CA kit will help in guiding treatment decisions for the breast cancer patients. Hence, owing to above mentioned factors, the market is expected to witness significant growth in the future.

Scope of the Report

Extraction of tissue or removing sample cells from a living body to determine the presence, cause, or extent of a disease is known as a biopsy. Cancer biopsy is a medical test in which a tissue or cells of the affected patient is taken to discover the presence, cause, or extent of cancer disease by which the individual got affected. The Cancer Biopsies Market is segmented by Product (Instrument, Kits and Consumables, and Services), Type (Tissue Biopsy, Cancer Surgical Biopsy, Liquid Biopsy, and Others), Application (Breast Cancer, Colorectal Cancer, Cervical Cancers, Lung Cancers, and Other Applications), End Users (Hospitals, Diagnostics Laboratories, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Product
Instrument
Kits and Consumables
Services
By Type
Tissue Biopsy
Cancer Surgical Biopsy
Liquid Biopsy
Others
By Application
Breast Cancer
Colorectal Cancer
Cervical Cancers
Lung Cancers
Other Applications
By End User
Hospitals
Diagnostic Laboratories
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Biopsy Application in Breast Cancer Segment is Expected to Grow Over the Forecast Period

The breast cancer segment is expected to have a positive growth over the forecast period. The rising burden of breast cancer is a key factor driving the market. The World Health Organization stated that in 2020, women diagnosed with breast cancer were 2.3 million, and 685 000 deaths were reported globally. Women who were diagnosed with breast cancer in the past 5 years and are alive were 7.8 million globally.

In addition, a study was initiated in 2019 named 'MRI-targeted Biopsy of the Prostate' to evaluate the clinical significance of prostate cancer detection with MRI targeted biopsy. It is being studied specifically in prostate cancer and prostate neoplasm. Also, a study titled 'Role of Ultrasound-Guided Lymph Node Biopsy in Axillary Staging of Breast Cancer' which was initiated in 2018 was studying the role of Ultrasound-guided axillary lymph nodes FNAC and\or CNB in breast cancer. The above conditions show that the incidence of breast cancer disease and technological advancements in the cancer biopsies market in the breast cancer application segment is expected to have a promising growth rate for the forecast period.

CAGR

North America Dominates the Market and Expected to do Same in the Forecast Period.

North America holds the major market share in the Cancer Biopsies market. The rising incidence of cancer diseases, the rising elderly population, technological advancements are key factors attributed to the growth rate of the cancer biopsies market. National Cancer Institute estimated that 43% of all cancers diagnosed in men are lung, colorectal,  and prostate cancers and the most common cancers in women are breast, lung, and colorectal which accounts for 50% of new cancers diagnosed in 2020 in the United States.

Foundation Medicine, Inc, an United States company based in Cambridge, Massachusetts which develops, manufactures, and sells genomic profiling assays based on next-generation sequencing technology for hematologic malignancies, solid tumors,  and sarcomas, announced that the Food and Drug Administration (FDA) approved its FoundationOne CDx, in 2020, which is considered the first FDA-approved tissue-based broad companion diagnostic (CDx) that is validated for all solid tumors both clinically and analytically.

According to the American Cancer Society in 2020, 1,806,590 new cancer cases and 606,520 cancer deaths were estimated in the United States. With rising awareness on preventive care and early diagnosis especially with the technological development of liquid biopsies in recent time, the rate of cancer survivors has increased potentially. According to National Cancer Institute, it is estimated the cancer survivors were projected to increase to 22.2 million by 2030 from 16.9 million in 2019. Hence, considering above mentioned factors, the market is expected to witness significant growth in the future.

Geo

Competitive Landscape

The Cancer Biopsies market is moderately competitive with several players across the globe. In terms of market share, few of the major players currently dominate the market.  With the rising patient awareness levels and high prevalence of cancer diseases, especially the recent developments in liquid biopsies, many regional players are expected to be part of the cancer biopsies market over the forecast period.  Some of the major players of the market are  QIAGEN N.V, Illumina, Inc., Becton, Dickinson and Company,  Myriad Genetics, Thermo Fisher Scientific, Inc., etc

Recent Developments

In 2021, Hologic announced acquiring SOMATEX , a medical device manufacturing company which is specialized in minimally invasive disposable instruments, breast care, biopsies, etc.

In August 2020, the U.S. Food and Drug Administration approved the first liquid biopsy ‘Guardant360 CDx’ which is said to be the next-generation sequencing companion diagnostic test. Guardant360 CDx – P200010 is the product of Guardant Health, Inc.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Burden of Oncology Disorders and Increase in Adoption of Liquid Biopsies

      2. 4.2.2 Advancement in Technologies

      3. 4.2.3 Rising Awareness on Inherited Oncology Disorders and Genetic Testing

    3. 4.3 Market Restraints

      1. 4.3.1 Associated Risks with Biopsy Procedures

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product

      1. 5.1.1 Instrument

      2. 5.1.2 Kits and Consumables

      3. 5.1.3 Services

    2. 5.2 By Type

      1. 5.2.1 Tissue Biopsy

      2. 5.2.2 Cancer Surgical Biopsy

      3. 5.2.3 Liquid Biopsy

      4. 5.2.4 Others

    3. 5.3 By Application

      1. 5.3.1 Breast Cancer

      2. 5.3.2 Colorectal Cancer

      3. 5.3.3 Cervical Cancers

      4. 5.3.4 Lung Cancers

      5. 5.3.5 Other Applications

    4. 5.4 By End User

      1. 5.4.1 Hospitals

      2. 5.4.2 Diagnostic Laboratories

      3. 5.4.3 Others

    5. 5.5 Geography

      1. 5.5.1 North America

        1. 5.5.1.1 United States

        2. 5.5.1.2 Canada

        3. 5.5.1.3 Mexico

      2. 5.5.2 Europe

        1. 5.5.2.1 Germany

        2. 5.5.2.2 United Kingdom

        3. 5.5.2.3 France

        4. 5.5.2.4 Italy

        5. 5.5.2.5 Spain

        6. 5.5.2.6 Rest of Europe

      3. 5.5.3 Asia-Pacific

        1. 5.5.3.1 China

        2. 5.5.3.2 Japan

        3. 5.5.3.3 India

        4. 5.5.3.4 Australia

        5. 5.5.3.5 South Korea

        6. 5.5.3.6 Rest of Asia-Pacific

      4. 5.5.4 Middle East and Africa

        1. 5.5.4.1 GCC

        2. 5.5.4.2 South Africa

        3. 5.5.4.3 Rest of Middle East and Africa

      5. 5.5.5 South America

        1. 5.5.5.1 Brazil

        2. 5.5.5.2 Argentina

        3. 5.5.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 QIAGEN N.V

      2. 6.1.2 Illumina, Inc.

      3. 6.1.3 Becton, Dickinson and Company

      4. 6.1.4 Myriad Genetics

      5. 6.1.5 Thermo Fisher Scientific, Inc.

      6. 6.1.6 BIOCEPT, INC.

      7. 6.1.7 ANGLE plc

      8. 6.1.8 Hologic, Inc.

      9. 6.1.9 Lucence Diagnostics Pte. Ltd.

      10. 6.1.10 Danaher Corporation

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Cancer Biopsies Market market is studied from 2018 - 2026.

The Global Cancer Biopsies Market is growing at a CAGR of 6.5% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Illumina, Inc., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, QIAGEN N.V, Myriad Genetics are the major companies operating in Global Cancer Biopsies Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!